Funder: Eli Lilly and Company
Due Dates: February 15, 2026: Efficacy of Lebrikizumab in fibrosing skin conditions | February 15, 2026: Impact of lebrikizumab on post-inflammatory dyspigmentation | June 15, 2026: Real-world effectiveness of mirkizumab in IBD (Canada)
Funding Amounts: Financial support and/or study drug provision; award size and duration are RFP-specific and not publicly specified.
Summary: Supports investigator-initiated clinical research aligned with Lilly's targeted RFPs in dermatology and gastroenterology.